JW Jungwooje Yak Conducts Bravo Campaign to Commemorate World Hemophilia Day

JW Pharmaceutical announced on the 17th that it will carry out the 'Bravo Campaign' to raise awareness about hemophilia in celebration of World Hemophilia Day.

JW Pharmaceutical employees are participating in the '4.17-second Stopwatch' event in the lobby of the headquarters in Seocho-dong, Seoul.
[Photo by JW Pharmaceutical]

April 17th is World Hemophilia Day, established in 1989 by the World Federation of Hemophilia (WFH) to increase social awareness of hemophilia and bleeding disorders. This year, the federation adopted the slogan "Access for All: Prevention of Bleeding as a Global Standard of Care" to emphasize improving treatment accessibility and prophylaxis for hemophilia patients.

To raise public awareness of hemophilia and commemorate Hemophilia Day, JW Pharmaceutical uploaded a video titled "Curious About Hemophilia" on its official YouTube channel. The video features Professor Youngsil Park from Kyung Hee University College of Medicine explaining hemophilia in women. Additionally, on the same day, a "4.17-second Stopwatch" event was held in the lobby of the Seoul Seocho-dong headquarters, where employees who stopped the stopwatch at exactly 4.17 seconds received commemorative gifts.

JW Pharmaceutical plans to continue activities aimed at improving awareness of rare diseases, including hemophilia. A JW Pharmaceutical representative stated, "We will continue to carry out various activities to raise social interest in hemophilia."

Hemophilia is a bleeding disorder caused by a deficiency of clotting factors in the blood, resulting in easy bleeding and difficulty stopping bleeding even from minor wounds. It is a rare disease occurring in about one in 10,000 people. According to the Hemophilia Foundation White Paper published by the Korea Hemophilia Foundation, approximately 2,500 patients are registered in South Korea.

In 2020, JW Pharmaceutical launched 'Hemlibra,' a treatment for severe hemophilia A. Hemlibra is a therapy for hemophilia A caused by a deficiency of clotting factor VIII. It simultaneously binds to clotting factors IX and X, mimicking the action mechanism of factor VIII. In February, the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee recognized its appropriateness for insurance coverage as a prophylactic treatment for severe hemophilia A patients without inhibitors, and it is expected to be launched soon with insurance benefits.

This content was produced with the assistance of AI translation services.